Updated:
Moleculin Biotech, Inc.
Groundbreaking Cancer Therapies | Moleculin Biotech, Inc. (NASDAQ: MBRX) is a clinical stage pharmaceutical company focused on the development of a broad...
Overview
Groundbreaking Cancer Therapies | Moleculin Biotech, Inc. (NASDAQ: MBRX) is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Company’s lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
General information
Frequently asked questions
What is Moleculin Biotech's lead drug candidate?
Moleculin's lead candidate is Annamycin, a next-generation anthracycline designed to treat acute myeloid leukemia and soft tissue sarcoma. It is in Phase 2 clinical trials as of 2025 (per SEC filings and press releases).
What therapeutic areas does Moleculin focus on?
Moleculin focuses on oncology, specifically drug-resistant cancers, and broad-spectrum antiviral therapies. Its pipeline includes Annamycin for AML and soft tissue sarcoma, plus WP1066 for brain tumors and pancreatic cancer.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: